ZA202210409B - Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease - Google Patents
Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseInfo
- Publication number
- ZA202210409B ZA202210409B ZA2022/10409A ZA202210409A ZA202210409B ZA 202210409 B ZA202210409 B ZA 202210409B ZA 2022/10409 A ZA2022/10409 A ZA 2022/10409A ZA 202210409 A ZA202210409 A ZA 202210409A ZA 202210409 B ZA202210409 B ZA 202210409B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- neurodegenerative
- compositions
- treatment
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980143P | 2020-02-21 | 2020-02-21 | |
| PCT/US2021/019113 WO2021168446A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202210409B true ZA202210409B (en) | 2024-01-31 |
Family
ID=77391353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/10409A ZA202210409B (en) | 2020-02-21 | 2022-09-20 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240018146A1 (enExample) |
| EP (1) | EP4106874A4 (enExample) |
| JP (2) | JP2023515101A (enExample) |
| KR (1) | KR20220158290A (enExample) |
| CN (1) | CN115515682B (enExample) |
| AU (1) | AU2021222053A1 (enExample) |
| BR (1) | BR112022016614A2 (enExample) |
| CA (1) | CA3168531A1 (enExample) |
| CO (1) | CO2022013603A2 (enExample) |
| CR (1) | CR20220476A (enExample) |
| EC (1) | ECSP22074210A (enExample) |
| IL (1) | IL295681A (enExample) |
| MX (1) | MX2022010309A (enExample) |
| PH (1) | PH12022552518A1 (enExample) |
| WO (1) | WO2021168446A1 (enExample) |
| ZA (1) | ZA202210409B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020253561A1 (en) * | 2019-04-03 | 2021-12-02 | Mitokinin, Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
| CN119752781B (zh) * | 2025-03-04 | 2025-07-01 | 中国农业大学 | 缓解成熟卵子老化的组合物、培养液、产品及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| JP5231251B2 (ja) * | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| EP2342178B1 (en) * | 2008-09-02 | 2016-09-28 | Sanofi | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| NZ710444A (en) * | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
| CA3067695A1 (en) * | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
-
2021
- 2021-02-22 BR BR112022016614A patent/BR112022016614A2/pt unknown
- 2021-02-22 CR CR20220476A patent/CR20220476A/es unknown
- 2021-02-22 CN CN202180025593.5A patent/CN115515682B/zh active Active
- 2021-02-22 AU AU2021222053A patent/AU2021222053A1/en active Pending
- 2021-02-22 CA CA3168531A patent/CA3168531A1/en active Pending
- 2021-02-22 PH PH1/2022/552518A patent/PH12022552518A1/en unknown
- 2021-02-22 WO PCT/US2021/019113 patent/WO2021168446A1/en not_active Ceased
- 2021-02-22 KR KR1020227032526A patent/KR20220158290A/ko active Pending
- 2021-02-22 US US17/801,450 patent/US20240018146A1/en active Pending
- 2021-02-22 IL IL295681A patent/IL295681A/en unknown
- 2021-02-22 JP JP2022550119A patent/JP2023515101A/ja not_active Withdrawn
- 2021-02-22 EP EP21757063.9A patent/EP4106874A4/en active Pending
- 2021-02-22 MX MX2022010309A patent/MX2022010309A/es unknown
-
2022
- 2022-09-20 ZA ZA2022/10409A patent/ZA202210409B/en unknown
- 2022-09-21 CO CONC2022/0013603A patent/CO2022013603A2/es unknown
- 2022-09-21 EC ECSENADI202274210A patent/ECSP22074210A/es unknown
-
2025
- 2025-05-09 JP JP2025078577A patent/JP2025142197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220158290A (ko) | 2022-11-30 |
| MX2022010309A (es) | 2022-11-14 |
| AU2021222053A1 (en) | 2022-09-15 |
| JP2023515101A (ja) | 2023-04-12 |
| CN115515682A (zh) | 2022-12-23 |
| EP4106874A4 (en) | 2024-03-20 |
| ECSP22074210A (es) | 2023-02-28 |
| IL295681A (en) | 2022-10-01 |
| US20240018146A1 (en) | 2024-01-18 |
| BR112022016614A2 (pt) | 2022-12-13 |
| CA3168531A1 (en) | 2021-08-26 |
| EP4106874A1 (en) | 2022-12-28 |
| JP2025142197A (ja) | 2025-09-30 |
| CO2022013603A2 (es) | 2023-03-17 |
| CR20220476A (es) | 2023-05-31 |
| WO2021168446A1 (en) | 2021-08-26 |
| CN115515682B (zh) | 2024-06-21 |
| PH12022552518A1 (en) | 2024-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012129A (es) | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. | |
| ZA202403426B (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| CO2022014876A2 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| ZA202210409B (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| MX2022014955A (es) | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| SA522441554B1 (ar) | Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها | |
| ECSP22009803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| ZA202306956B (en) | Long acting injectable compositions of cariprazine or its pharmaceutically acceptable salts | |
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| CA2904533C (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| EP4606433A8 (en) | FORMULATIONS CONTAINING HETEROCYCLIC PROTEIN KINASE INHIBITORS | |
| PH12021552376A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| CR20240353A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| CR20230366A (es) | Fracciones que prolongan la semivida y métodos de uso de estas | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| MX2022009851A (es) | Compuestos útiles para inhibir la cetohexocinasa y métodos para elaborarlos y utilizarlos. |